SELLAS Life Sciences Group (id:5861 SLS)
1.17 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 1:09:08 PM)
Exchange closed, opens in 1 day 20 hours
About SELLAS Life Sciences Group
Market Capitalization 90.79M
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Headquarters (address) |
Times Square Tower New York 10036 NY United States |
| Phone | 646 200 5278 |
| Website | https://www.sellaslifesciences.com |
| Employees | 16 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | SLS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.500 - 1.72 |
| Market Capitalization | 90.79M |
| P/E trailing | -0.873 |
| P/E forward | -3.00 |
| Price/Book | 5.02 |
| Beta | 2.40 |
| EPS | -0.900 |
| EPS United States (ID:6, base:3399) | 24.27 |